Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Ahmad Hussein Awada

Department : Medical oncology, Clinical Trials Conduct Unit (CTCU) , Medicine department
 
ahmad.awada [at] bordet.be

Publications

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Authors : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Year : 2021
Journal : Target Oncol

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors.

Authors : Spicer J, Marabelle A, Baurain JF, Jebsen NL, Jøssang DE, Awada A, Kristeleit R, Loirat D, Lazaridis G, Jungels C, Brunsvig P, Nicolaisen B, Saunders A, Patel H, Galon J, Hermitte F, Camilio KA, Mauseth B, Sundvold V, Sveinbjørnsson B, Rekdal Ø
Year : 2021
Journal : Clin Cancer Res

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Authors : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Year : 2021
Journal : Target Oncol

Targeted therapy for breast cancer in older patients.

Authors : Pondé N, Wildiers H, Awada A, de Azambuja E, Deliens C, Dal Lago L
Year : 2020
Journal : J Geriatr Oncol

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.

Authors : van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM
Year : 2020
Journal : Br J Cancer

More publications »

Follow us!

Youtube

Exclusive images of the new Jules Bordet Institute!

The new Institut Jules Bordet, a building for the practice of medical excellence now and in the future. Meeting at the end of November 2021 on the ULB campus in Anderlecht.